RV144-like trial in macaques using ALVAC-SIV & gp120 induces innate immunity and increases the frequency of NK22 & NKG2A+ cells in mucosal tissues

Samankaltaisia teoksia

• Myeloid Cell Crosstalk Regulates the Efficacy of the DNA/ALVAC/gp120 HIV Vaccine Candidate
  Tekijä: Vaccari, Monica, et al.
  Julkaistu: (2019)
• Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIV(mac251) Acquisition
  Tekijä: Gordon, Shari N., et al.
  Julkaistu: (2016)
• Do CD16+NKG2A+NK Cells Recruited to the Gut Combined with Passively Administered SIV Specific Antibodies Prevent SIV(mac251) Acquisition in Macaques?
  Tekijä: Liyanage, Namal P.M., et al.
  Julkaistu: (2014)
• Antibodies with High Avidity to the gp120 Envelope Protein in Protection from Simian Immunodeficiency Virus SIV(mac251) Acquisition in an Immunization Regimen That Mimics the RV-144 Thai Trial
  Tekijä: Pegu, Poonam, et al.
  Julkaistu: (2013)
• Engagement of monocytes, NK cells, and CD4(+) Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIV(mac251) vaginal acquisition
  Tekijä: Gorini, Giacomo, et al.
  Julkaistu: (2020)